Patient-delivered partner treatment for Trichomonas vaginalis infection: A randomized controlled trial

Sexually Transmitted Diseases

Volumn 33, Issue 7, 2006, Pages 445-450

  Kissinger, Patricia ^a,d   Schmidt, Norine ^a   Mohammed, Hamish ^a   Leichliter, Jami S ^b   Gift, Thomas L ^b   Meadors, Bernadette ^c   Sanders, Cheryl ^a   Farley, Thomas A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT COUNSELING; PATIENT REFERRAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TRICHOMONAS VAGINALIS; TRICHOMONIASIS;

ADULT; ANIMALS; ANTIPROTOZOAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; LOUISIANA; MALE; METRONIDAZOLE; PREVENTIVE HEALTH SERVICES; REFERRAL AND CONSULTATION; SEXUAL PARTNERS; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS;

EID: 33745649218     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000204511.84485.4c     Document Type: Article

References (33)

1. Swygard H, Sena AC, Hobbs MM, et al. Trichomoniasis: clinical manifestations, diagnosis and management. Sex Transm Dis 2004; 80:91-105.
2. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000; 27:284-288.
3. Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis 2004; 31:547-551.
4. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002; 34:1406-1411.
5. Buve A, Weiss HA, Laga M, et al. The epidemiology of trichomoniasis in women in four African cities. AIDS 2001; 15(suppl 4):S89-96.
6. Cu-Uvin S, Hogan JW, Warren D, et al. Prevalence of lower genital tract infections among human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women: HIV Epidemiology Research Study Group. Clin Infect Dis 1999; 29:1145-1150.
7. Magnus M, Clark R, Myers L, et al. Trichomonas vaginalis among HIV-infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis 2003; 30:839-843.
8. Hogben M, McCree D, Golden M. Patient-delivered partner therapy for sexually transmited diseases as practiced by U.S. physicians. Sex Transm Dis 2005; 32:101-105.
9. Chacko M, Smith P, Kozinetz C. Understanding partner notification (patient self-referral method) by young women. J Pediatr Adolesc Gynecol 2000; 13:27-32.
10. Golden M, Whittington W, Handsfield H, et al. Impact of expedited sex partner treatment on recurrent or persistent gonorrhea and chlamydial infection: a randomized controlled trial. N Engl J Med 2005; 352:676-685.
11. Fortenberry J, Brizendine E, Katz B, et al. The role of self-efficacy and relationship quality in partner notification by adolescents with sexually transmitted infections. Arch Pediatr Adolesc Med 2002; 156:1133-1137.
12. Oh M, Boker J, Genuardi F, et al. Sexual contact tracing outcome in adolescent chlamydial and gonococcal cervicitis cases. J Adolesc Health 1996; 18:4-9.
13. Potterat J, Rothenberg R. The case-finding effectiveness of self-referral system for gonorrhea: a preliminary report. Am J Public Health 1977; 67:174-176.
14. Woodhouse D, Potterat J, Muth J, et al. A civilian-military partnership to reduce the incidence of gonorrhea. Public Health Rep 1985; 100:61-65.
15. Patel H, Viswalingam N, Goh B. Chlamydia ocular infection: efficacy of partner notification by patient referral. Int J STD AIDS 1994; 5:244-247.
16. van de Laar M, Termorshuizen F, van den Hoel A. Partner referral by patients with gonorrhea and chlamydial infection: case-fining observations. Sex Transm Dis 1997; 24:334-342.
17. Golden M, Whittington W, Handsfield H, et al. Partner management for gonococcal and chlamydial infection: expansion of public health services to the private sector and expedited sex partner treatment through a partnership with commercial pharmacies. Sex Transm Dis 2001; 26:658-665.
18. Kissinger P, Brown R, Reed K, et al. Effectiveness of patient-deliverd partner medication for preventing recurrent Chlamydia trachomatis. Sex Transm Dis 1998; 74:331-333.
19. Ramstedt L, Johannisson G. Contact tracing in the control of genital Chlamydia trachomatis infection. Int J STD AIDS 1991; 2:116-118.
20. Nuwaha F, Kambunga F, Nsubuga P, et al. Efficacy of patient-delivered partner medication in the treatment of sexual partners in Uganda. Sex Transm Dis 2001; 28:105-110.
21. Schillinger J, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. Sex Transm Dis 2003; 30:49-56.
22. Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized controlled trial. Clin Infect Dis 2005; 41:623-629.
23. Golden M, Anukam U, Williams D, et al. The legal status of patient-delivered partner therapy for sexually transmitted infections in the United States: a national survey of state medical and pharmacy boards. Sex Transm Dis 2005; 32:112-114.
24. Medical Economics Company. 2003 Drug Topics Red Book. Montvale: Thomson PDR, 2003.
25. Steckler J, Bachman L, Brotman R, et al. Concurrent sexually transmitted infections (STIs) in sex partners of patients with selected STIs: implications for patient-delivered partner therapy. Clin Infect Dis 2005; 40:787-803.
26. Faxelid E, Tembo G, Ndulo J, et al. Individual counseling of patients with sexually transmitted diseases: a way to improve partner notification. Sex Transm Dis 1996; 23:289-292.
27. Wright A, Chipppindale S, Mercey D. Investigation into the acceptability and effectiveness of a new contact slip in the management of Chlamydia trachomatis at a London genitourinary medicine clinic. Sex Transm Dis 2002; 78:422-424.
28. Lossick J. Single-dose metronidazole treatment of vaginal trichomoniasis. Obstet Gynecol 1980; 56:508-510.
29. Schmid G, Narcisi E, Mosure D, et al. Prevalence of metronidazole- resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001; 46:545-549.
30. Snipes LJ, Gamard PM, Narcisi EM, et al. Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates. J Clin Microbiol 2000; 38:3004-3009.
31. Das S, Huengsberg M, Shahmanesh M. Treatment failure of vaginal trichomoniasis in clinical practice [in process citation]. Int J STD AIDS 2005; 16:284-286.
32. Chesson H, Blandford J, Gift T, et al. The estimated direct medical cost of sexually transmitted disease among American youth, 2000. Perspect Sex Reprod Health 2004; 36:11-19.
33. Bureau of Labor Statistics. Consumer Price Index: All Urban Consumers [database on the internet]. Washington, DC: Bureau of Labor Statistics, 2005 [cited 2005 Sep 14]. Available from: http://www.bls.gov/cpi/home.htm.